Pfizer Plans To Restart Tanezumab Trials In 2014

While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.